

Lifeloc Technologies
Annual Shareholders Meeting
May 18, 2020



Committed to safer roads and
workplaces worldwide

Welcome Shareholders

- Agenda
- Shareholder Votes per Proxy Statement
- State of the Company

Lifeloc Technologies

Safe Harbor Agreement

This presentation contains forward-looking statements which reflect management's expectations regarding Lifeloc's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Where possible words such as "plans," "expects" or "does not expect," "budget," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved, have been used to identify these forward-looking statements. Although the forward-looking statements contained in this presentation reflect management's current assumptions based upon information currently available to management and based upon that which management believes to be reasonable assumptions, Lifeloc cannot be certain that actual results will be consistent with these forward looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Lifeloc's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: international and domestic operations, customer demand, regulatory matters credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; use of non-GAAP financial measures; significant shareholder; supply arrangements; and dependence upon key management personnel and executives. For more details, please see the "Risk Factors" section of our SEC filing.

Although Lifeloc has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, as noted above, you should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this presentation and, except as required by law, Lifeloc assumes no obligation to update or revise them to reflect new events or circumstances.

Lifeloc Today

- Installed base in over 65 countries.
- Global penetration in both workplace testing and law enforcement
- Core Business is strongly cash flow positive
- Solid balance sheet
- \$8.75 million sales, 36 FTE, 2019
- Big growth opportunities in offender monitoring and real time drug testing

2019 Highlights

- 1) Company revenue at \$8.75 million
- 2) 18th consecutive profitable year
- 3) Product Releases - LX9, LT7, EasyCal[®] G2

- EasyCal[®] is a registered trademark of Lifeloc Technologies, Inc.

Profit and Loss 2019

Income Statement	2019	2018
Revenue	\$ 8,751,823	\$ 8,437,654
Gross Profit	\$ 3,936,003	\$ 3,809,251
Gross Margin	45.0%	45.1%
R&D	\$ 1,038,227	\$ 1,121,827
Sales	\$ 1,240,773	\$ 1,251,388
General and Admin	\$ 1,175,788	\$ 1,165,413
Pretax Income	\$ 687,362	\$ 234,597
Net Income	\$ 625,826	\$ 217,164

COVID-19 Pandemic

The global pandemic has had a significant impact on business since February, resulting in following actions:

- Hiring freeze since end of January
- No overtime
- Reducing workplace density
- Participation in PPP
- Exploration of grants to utilize our technology disease monitoring
- Evaluate more steps as needed

Lifeloc Growth Strategy

Lifeloc seeks to grow and exceed \$100 million annual revenue

1) Drug of Abuse – Real time testing

Spin Dx and Marijuana breathalyzer - Top Priority

2) Recurring Revenue

Monitoring business

3) Grow the Pie


Move to higher value-added applications and licensing

4) Grow the Core

Everything depends on this solid base to fund growth opportunities


Action towards Goals

1) Drug of Abuse




Added personnel with relevant experience

2) Recurring Revenue




RADAR Model 200 in final testing

3) Grow the Pie



Easycal G2 with RFID

4) Grow the Core




LX9, LT7 form solid base for next decade

Drugs of Abuse

- The DOA market is ripe for a new technology play to replace traditional blood (expensive) and urine testing (limited utility)
- The drug testing needs are enormous and growing
- No one company provides a real time, quantitative drug testing solution to the marketplace

SpinDx Development Status

- SpinDx methodology determined to be the most sensitive and discriminating portable method
- Lifeloc has existing channel to both Law Enforcement and Workplace markets
- Demonstrated sensitivity down to 5 ng/ml and THC capture from vapor
- More development needed before field testing



R.A.D.A.R.® Opportunity

- R.A.D.A.R. model 200 is in final testing
- New model has updated communication, improved mechanical reliability and GPS accuracy
- R.A.D.A.R. business model shifts to recurring revenue stream through leasing and monitoring fees
- RADAR is part of an offender management system as an alternative to incarceration
- Patented biometrics and automated reporting center create a sustainable competitive advantage



R.A.D.A.R.® is a registered trademark of Lifeloc Technologies, Inc.

Easycal[®] G2



Calibrates all LifeLoc Professional models

RFID reader upgrades automation and locks in tank sales

Additional languages - simple file upload

Patent Protected

New Platform LX9 and LT7



Test down to -10°C

Ambidextrous

Rechargeable battery option

Color display

GPS, WiFi, Bluetooth

Data uploads

Customization through
configuration files

Additional languages - simple
file upload

Patents pending

New Platform LX9 and LT7



Now selling in:

Arizona

California

Finland

India

Indonesia

Malaysia

Mexico

Tonga

Lifeloc Growth Summary

Marijuana breathalyzer is an enormous need and top priority

Shift to recurring revenue business model: RADAR, data management

Core growth expected as new platform opens market opportunities

Invest as needed in the core business for solid base

Marketing

Engage marketing expertise to coordinate product launches

Updating marketing materials, messaging and website

Critical to get the most out of product investments

Thank you Lifeloc shareholders for
your continued support